Autopsy report · NCT04221451
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2
Cause of deathOther
“Discontinued based on the absence of positive trends on clinical endpoints.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 4 years 6 months before it stopped.
- 75 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Genzyme, a Sanofi Company
- Sponsor type
- Industry
- Conditions
- Tay-Sachs Disease; Sandhoff Disease
- Interventions
- venglustat GZ402671; placebo
- Participants
- 75
- Sites
- 23
- Countries
- Argentina, Brazil, Czechia, France, Germany, Italy, Japan, Portugal, Russia, Spain, Turkey (Türkiye), United Kingdom and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.